Abstract 1589P
Background
In addition to the structural/medical barriers that trial centres face in including patients, the disparities that patients face prevents some groups from receiving the expected benefit from the studies and the results from representing the entire population. This study assessed the barriers to recruiting individuals in phase one trials who were referred to clinical research facility located in central London.
Methods
Records of patients who were referred to Guy's Cancer Early Phase Trials Unit between January and December 2023 were retrospectively reviewed. Baseline patient characteristics and barriers to trial enrolment were recorded and descriptive statistics were presented. The distrubition of new referrals by age, cancer types, ethnicity, and socioeconomic status defined by Index of Multiple Deprivation (IMD,1 - most deprived; 10 - least deprived) was also assessed by comparing with our group's historic data published in 2013 in Journal of Clinical Oncology.
Results
We reviewed 206 new patients in 2023. Median age of the group was 63, and 52.4% of patient were male. GI, thoracic, gyneacological and urological malignancies were the most common tumour groups (37%, 19%, 18%, and 14% respectively). Of whole group, 33.9% of patients were referred after two lines of previous treatment. 37 patients (17.9%) were recruited to a trial annually. Most common barrier to be recruited to a trial is that the center has no potential trial to offer (N=59, 35.9%), followed by failure to meet radiological criteria (11.2%), and poor performance status (10.0%) 22 patients (10.6%) were from most deprivated (IMD 1-2) background. Our historic data from 2013 showed 21.9% of patients had been referred from most deprivated background. There was a white-ethnicitiy domination in current and historic data (71.5% and 74.2%, retrospectively).
Conclusions
An increasing number of new patients are being referred to our centre. Among the prominent recruitment barriers are the lack of appropriate studies and non-compliance with medical criteria. The decrease in the rate of patients from low socioeconomic backgrounds is striking compared to the historical data of our center. Further efforts should be made to identify the potential causes of this situation and to improve it.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10